Skip to Content

Prostate Cancer Clinical Trials

SPORE: Tissue, Blood, and Urine Banking for the Robert H. Lurie Comprehensive Cancer Center Prostate Tissue Bank

Aims: This study involves the banking (storing) of prostate tissue, blood and urine. Information from the patient's medical records and treatment will be followed for an indefinite amount of time up to 75 years or more. The purpose of the study is to enable cancer researchers and other investigators attain a better understanding of the development of prostate cancer, its treatment, prevention, and cure.
Diagnosis: Prostate
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH01-129
Sponsor: Robert H. Lurie Comprehensive Cancer Center
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

PCCTC c16-168: A Randomized Phase II  Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) with DNA Repair Defects
Aims: The main purpose is to study abiraterone alone, olaparib alone or the combination of the two drugs to see which works better.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH17/285
Sponsor: University of Chicago/PCCTC
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

NRG GU-008: A Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE)
Aims: The main purpose is to study is to see if we can lengthen the time without your prostate cancer spreading by adding 2 new hormone therapy drugs to the usual combination of hormone therapy and radiation therapy.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH21-206
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

EA8183: A Phase III Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Aims: The main purpose is to study is to see if adding daralutamide to standard androgen deprivation therapy is better than standard androgen deprivation therapy alone and preventing cancer from recurring.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH21-133
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

AFT-19: A Phase 3 Study of Androgen Annihiliation in High-Risk Biochemically Relapsed Prostate Cancer
Aims: The purpose of this study which of the 3 treatment regimens is better at treating prostate Cancer:  1) degarelix, 2) degarelix and apalutamide, or 3) degarelix and apalutamide and abiraterone acetate/prednisone
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH17-287
Sponsor: Alliance Foundation Trial
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

A031501: Phase III randomized "Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma " (AMBASSADOR) versus observation
Aims: The main purpose of this study is to see if pembrolizumab is the same, better, or worse thatn the usual approach to treat bladder cancer.
Principal Investigator: Nicklas Pfanzelter, MD
IRB Approval Number: EH20-309
Sponsor: Alliance
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment:
Yes

Genomic Profiling and Clinical Outcomes in Metastatic Castrate-Resistant Prostate Cancer
Aims: The main purpose of this study is to see if genomic testing in men with metatstatic castration resistance prostate cancer is clinically relevant and if it will help guide physician decision making.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH20-300
Sponsor: NorthShore
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment:
Yes

J1557: Overcoming Drug Resistance in Metastatic Castration-Resitant Prostate Cancer with Novel Combination of TGF-G Recepto Inhibitor LY2157299 and Enzalutamide: A Randomized, Multi-Site Phase II Study
Aims: The purpose is to test the effectiveness and safety of combining enzalutamide with LY2157299 in men with advanced castrate resistant prostate cancer.
Principal Investigator: 
Daniel Shevrin, MD
IRB Approval Number: 
EH19-186
Sponsor: 
Johns Hopkins University
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment:
 Yes